€95.9m market cap
€13.86 last close
Adocia is a French biotech company focused on innovative formulations of approved proteins. The company features the BioChaperone technology platform, which has generated six products in clinical stage; the most advanced is BioChaperone Lispro, which is Phase III ready. Adocia has four preclinical products; three are due to start clinical trials in 2018.
Investment summary
FY18 accounts show cash of €39.8m after the April 2018 payment of €37.2m ($50m) for the deal with Tonghua Dongbao (THDB) in China. The €11.9m 2018 arbitration award ($11.6m plus $1.6m interest) against Lilly should be received in 2019 after further legal aspects are cleared. A successful single-dose Phase I of BioChaperone (BC) pramlintide insulin could lead to a multiple-dose study in Q219. A European/US Phase III of BC Lispro can be run after a short bridging study and if a partner is found.
Sector |
|---|
| Healthcare |
Share price graph
Price performance
% |
1m |
3m |
12m |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
| *% relative to local index | |||||||||||||||
Key management |
|
|---|---|
| Gerard Soula | CEO |
| Valerie Danaguezian | CFO |
| Remi Soula | Director of Business Development |
You may also be interested in…
- 4SC
- Acacia Pharma
- Acarix
- ADL Bionatur Solutions
- ASIT biotech
- Basilea Pharmaceutica
- BioPorto Diagnostics
- Bonesupport
- Brighter
- Cantargia
- Carmat
- Celyad
- Deinove
- Formycon
- Herantis Pharma
- Hybrigenics
- Immunicum
- Immunovia
- Kiadis Pharma
- Laboratorios Farmacéuticos ROVI
- MagForce
- Medigene
- MOLOGEN
- Nanobiotix
- NeuroVive Pharmaceutical
- Newron Pharmaceuticals
- Nuevolution
- Oncology Venture
- Onxeo
- Orexo
- Oryzon Genomics
- OSE Immunotherapeutics
- Paion
- Photocure
- Pixium Vision
- Probiodrug
- Quantum Genomics
- RhoVac
- Ryvu Therapeutics
- Targovax
- Transgene
- TxCell
- Xbrane Biopharma